| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | FMK | GDSC1000 | pan-cancer | AAC | -0.024 | 0.5 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | -0.022 | 0.5 |
| mRNA | KIN001-244 | GDSC1000 | pan-cancer | AAC | -0.02 | 0.5 |
| mRNA | OSI-930 | GDSC1000 | pan-cancer | AAC | -0.022 | 0.5 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.022 | 0.5 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.029 | 0.5 |
| mRNA | Vorinostat | CTRPv2 | pan-cancer | AAC | 0.021 | 0.5 |
| mRNA | BRD-A86708339 | CTRPv2 | pan-cancer | AAC | 0.031 | 0.5 |
| mRNA | NU-7441 | GDSC1000 | pan-cancer | AAC | -0.023 | 0.5 |
| mRNA | BRD1812 | CTRPv2 | pan-cancer | AAC | 0.022 | 0.5 |